Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Abbott Tenders for Bonds Before $16 Billion in Debt Issuance
Bloomberg
Saturday, October 27, 2012 - 11:37am
tags:
Abbott Laboratories
Eli Lilly And Company (LLY): Today's Featured Drugs Laggard
The Street
Saturday, October 27, 2012 - 11:36am
tags:
Eli Lilly
S&P downgrades Abbott Labs credit rating
Yahoo/AP
Saturday, October 27, 2012 - 11:36am
tags:
Abbott Laboratories
Merck Profit Beats Analyst Estimates on Drug Sales
Bloomberg
Saturday, October 27, 2012 - 11:35am
tags:
Merck, earnings
Why ImmunoGen’s Shares Had a Bad Reaction
Motley Fool
Saturday, October 27, 2012 - 11:34am
tags:
Immunogen
An Early Christmas for Flu Vaccine Companies?
Motley Fool
Saturday, October 27, 2012 - 11:33am
tags:
influenza, flu vaccines, vaccines
Why These 3 Biotech Stocks Are Winning
Motley Fool
Saturday, October 27, 2012 - 11:32am
tags:
Cyclacel, Gilead Sciences, Amarin
BioMarin Reports Narrower Loss
Yahoo/Zacks
Saturday, October 27, 2012 - 11:31am
tags:
Biomarin, earnings
Has Onyx Pharmaceuticals Become the Perfect Stock?
Motley Fool
Saturday, October 27, 2012 - 11:30am
tags:
ONYX Pharmaceuticals
Exelixis Stock Treads Water Ahead Of FDA Decision
Seeking Alpha
Saturday, October 27, 2012 - 11:30am
tags:
cabozantinib, medullary thyroid cancer, thyroid cancer
This Biotech Is Looking Good, Ready for More
Motley Fool
Saturday, October 27, 2012 - 11:29am
tags:
Biogen Idec
ImmunoGen's CEO Discusses F1Q13 Results - Earnings Call Transcript
Seeking Alpha
Saturday, October 27, 2012 - 11:28am
tags:
Immunogen
Will These Numbers from Charles River Laboratories International Be Good Enough for You?
Motley Fool
Saturday, October 27, 2012 - 11:28am
tags:
Charles River Laboratories
Richard Pearson Responds On Ziopharm
Seeking Alpha
Saturday, October 27, 2012 - 11:27am
tags:
Ziopharm, palifosfamide, sarcoma, small cell lung cancer
After Sharp Sell-Off, Can Alexion Pharmaceuticals' Stock Regain Its Health?
investors.com
Saturday, October 27, 2012 - 11:24am
tags:
Alexion
How Big A Dividend Will Abbott Pay After It Splits?
Seeking Alpha
Friday, October 26, 2012 - 11:20am
tags:
AbbVie, Abbott Labs, dividends
Study: Amazing early-stage R&D results rarely hold up in big trials
Fierce Biotech
Friday, October 26, 2012 - 11:19am
tags:
R&D, biotech, clinical trials
FDA Agrees to Speed Review of Ariad Drug
Motley Fool
Friday, October 26, 2012 - 11:15am
tags:
FDA, Ariad Pharma, Ponatinib, chronic myeloid leukemia, acute lymphoblastic leukemia
ImmunoGen 1st-quarter grows by 29 pct as it studies lung cancer drug and other products
Yahoo/AP
Friday, October 26, 2012 - 11:12am
tags:
earnings, Immunogen
European approval granted for Trajenta tablets as add-on therapy in Diabetes
Yahoo/Fly on the Wall
Friday, October 26, 2012 - 11:12am
tags:
Europe, Trajents, diabetes, Eli Lilly, Boehringer Ingelheim

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.